Prognostic significance of circRNAs expression in breast carcinoma patients: A meta analysis

Zizhen Zhou^{1†} Xiancai Li^{1†} Dewu Liu^{2*}

1Department of Burns, the First Affiliated Hospital of Nanchang University, Nanchang , China. † ZZZ and XCL contributed equally to this study.

Correspondence to : Dewu Liu, Department of Burns, The First Affiliated Hospital of Nanchang

University. No.17, Yongwaizhengjie Road, Donghu District Nanchang 330006, Jiangxi, China; E-mail addresses: dewuliu2@126.com

Financial support: This study was supported by the Postgraduate Innovation Special Foundation of Jiangxi Province (YC2020-B043)

Credit author statement

XC.L study concept and design, data collection; ZZ.Z data analyzing and article writing; DW.L Obtained funding and critically revised the manuscript.

All of the authors reviewed the manuscript and approved the final version.

Declaration of Competing Interest

The authors declare that there are no conflicts of interest.

Abstract

Objective: The aim of our study was to systematically evaluate the prognostic effects of various circrnas and to explore the prognostic value of circRNAs in breast cancer patients.

Methods: A systematical search was conducted on PubMed, Scopus, EMBASE, and the Cochrane Library databases. Eligible studies reporting on the association among circRNAs and prognostic values of breast cancer patients were included. Fixed-effects and random effects models were used to calculate the pooled hazard ratio values of overall survival and disease free survival. In addition, funnel plots were used to qualitatively analyze the publication bias.

Results:28 studies were included in our meta-analysis. The pooled hazard ratio values of overall survival and disease free survival related to different circRNAs expression in breast cancer patients were 1.68 (1.44-1.97), 2.63 (1.95-3.53).We have identified a total of 28 circRNAs including 19 significantly up-regulated expression circRNAs and 9 significantly down-regulated expression circRNAs in BC(breast cancer) patients. Moreover, all of them revealed mechanisms and have the function of promoting or inhibiting the proliferation, metastasis or invasion of breast cancer cells by acting on the corresponding target.

Conclusion: Overall, specific circRNAs are significantly associated with the prognosis of BC patients and potentially eligible for the prediction of patients survival. It also provides a potential value for clinical decision-making development and may serve as a promising circRNAs-based target therapy waiting for further elucidation.

(Key words) CircRNA; Breast cancer; Prognosis; Meta analysis

1.Introduction

Breast cancer (BC) is a common cancer that greatly affects globle women and is the leading cause of cancer death[1]. The incidence of BC has been reported to be on the rise over the past decade, in addition to the fact that female patients continue to have the highest mortality[2]. It is also reported that there were 2,088,000 new cases of BC, and 626,000 women died of BC worldwide in 2018. Although the diagnosis and treatment strategies of BC have been improved and the overall survival time of BC patients is relatively long, the prognosis of BC patients cannot achieve the expected effect due to the complex pathogenesis of breast cancer, the molecular characteristics of BC and the diverse clinical manifestations of BC patients. Therefore, it is urgent to better understand the key signaling pathways and find new therapeutic targets for more effective treatment of BC in order to improve the prognosis of BC patients.

Circular RNAs (circRNAs), a novel class of ncRNAs with 3'- and 5'-ends covalently linked in a closed loop structure, are ubiquitous in all eukaryotic cells[3-5]. However, circRNAs discovered in the early stage has always been considered as not functional. With the development of RNA sequencing technology and bioinformatics, circRNA's functionality has been gradually discovered and further studied[6]. Extensive studies[7, 8]have shown that circRNAs are abundant in eukaryotic cells and play a key role in human diseases, including BC, by binding to microrna (MIRS), interacting with RNA-binding proteins, and regulating transcription. CircRNAs can directly regulate protein expression through interaction with miRs, thereby promoting or inhibiting proliferation, invasion and metastasis of breast cancer cells [9]. Yang et al.[10]found that circ_0103552 expression significantly increased in breast cancer tissue samples and cells, and it was associated with clinical severity and poor prognosis, including advanced TNM stage and positive lymph node infiltration. It can directly play a carcinogenic role through the spongy action of Mir-1236. In addition, the upregulation of CIRc 0103552 can also promote cell growth, clonal formation, migration and invasion, and reduce apoptotic cells. A recent study [11]showed that the expression of circRNA_000554 in BC tissues was significantly lower than that in normal tissues, and the survival time of hsa circRNA 000554 with low expression was shorter than that of circRNA_000554 with overexpression. In addition, they found that circRNA_000554 with overexpression inhibited EMT, cell invasion and migration during breast cancer by decreasing Mir-182 and increasing ZFP36.

To sum up, circRNAs expression may affect the prognosis of breast cancer.In our study, we performed a meta analysis to summarize the prognostic significances of circRNAs in BC patients. Further prospective studies including more kinds of circRNAs are warranted in the future.

2.MATERIALS AND METHODS

2.1. Search strategy

A computerized literature search was performed in the PubMed, Scopus, EMBASE, and the Cochrane Library databases up to 25 november 2018. The search strategy of our study followed the terms such as: (a) "circRNA" or "circular RNA"; and (b) "breast cancer" or "breast carcinoma" or "breast carcinoma". In addition, we hand \Box searched the references of all relevant articles one by one if it is necessary. When the important data were not available, we tried to contact researchers of certain articles.

2.2. Inclusion and exclusion criteria

The article selection used the following inclusion and exclusion criteria for each study. A study that is eligible for inclusion must meet the following criteria:(1) Case control study or cohort study, including case group and control group;(2) Breast cancer patients were diagnosed by

pathologists;(3) Detection of circRNAs expression level, clinicopathological features, and prognosis of patients;(4)Overall survival (OS), disease-free survival (DFS), hazard ratio (HR), and 95 confidence interval (CI) can be obtained directly from the full text, or survival data can be extracted from kaplan-Meier survival curve.

Moreover, the exclusion articles all fitted the following criteria:(1)Studies not relevant to circRNA or BC;(2)Similar studies or repeated data in different articles;(3)Animal studies, comments, case reports, expert opinions, letters, etc.;(4)Without available data for analysis and the authors could not be contacted;(5) Non-English literature.

2.3. Data Extraction

The two authors (Xiancai Li and Zizhen Zhou) extracted data independently and got consensus finally. (A) baseline information for each study, including author, year of publication, nation of population enrolled, number of patients, circRNAs type,HR and 95% CI (OS/DFS), cut-off value, method, sample type, and follow-up. (B)we extracted the functions and targets related to the up-regulation and down-regulation of circRNA expression so as to illustrate the mechanism of circRNA's effect on breast cancer prognosis.

2.4. Statistical analysis

statistical analysis was conducted by Stata version 12.0. hazard ratios (HRs) and 95% confidence intervals (CIs) were utilized to evaluate OS/DFS .The chi \Box square test and the I² statistic were utilized to assess the between \Box study heterogeneity .P < 0. 01 was considered statistically significant. The heterogeneity among studies was calculated by Q and I² tests. P > 0.10 in combination with I² < 50% indicated low heterogeneity(note: I² <25% suggests low

heterogeneity; $25 \leq I^2 \leq 75\%$ suggests moderate heterogeneity; $I^2 > 75\%$ shows high

heterogeneity), which should use fixed-effect models. Otherwise, random-effect models would be used finally. For some studies from which we could not extract HR and corresponding 95% CI (OS/DFS) directly, Engauge Digitizer 4.1 software was applied to obtain the necessary points and the relevant data from Kaplan-Meier survival curves, then HR and corresponding 95% CI were calculated by published methods proposed by Tierney et al[12]. Additionally, forest plots of the pooled HR values and funnel plots used to analyse qualitatively publication bias were presented.

3. Results

3.1 Search results

The study search is shown in the flow diagram (Figure 1). 592 relevant articles were collected during the database search. 194 duplicate literatures were excluded, and 370 literatures were excluded after reading the titles and full texts. To sum up, 28 eligible studies were included in the present study. All the selected studies included 27 for OS, 5 for DFS analysis.

3.2 Study characteristics

The main features of each eligible study are summarized in details (Tables 1 and 2). The years for publication ranged from 2018 to 2020. Most of the studies taken into account refer to Asian population, especially china. The range of sample size in each study was from 30 to 350. Cut-off values of high or low circRNA expression were mostly median or mean. The range of mean duration of follow up was from 30 to 250 months. Moreover, Detection methods of circRNA expression were mainly quantitative real time polymerase chain reaction (RT PCR). Sample types were almost from tissues. As for clinical outcome indicators, 27 studies [10, 11, 13-34], [35-37] included overall survival (OS), 5 studies [19, 29, 31, 33, 38] included

disease-free survival (DFS). As shown in Table 3, nineteen types of circRNAs were recognized as tumor promoters and nine were tumor suppressors. 28 circrnas have corresponding targets and can promote or inhibit the proliferation, invasion and metastasis of breast cancer cells.

3.3 Meta-Analysis Findings

Random-effects and fixed-effects models were applied to evaluate the pooled hazard ratio (HR) and its corresponding 95% confidence interval (CI) of OS or DFS based on the heterogeneity level. The pooled HR value (95% CI) of OS which correlated with the expression of

circRNA was 1.68 (1.44-1.97) with moderate heterogeneity (I²=47.9%, P=0.003) and statistically

significant (P < 0. 00001) (Figure 2).Therefore,the random effects models was used. And the pooled HR value (95% CI) of DFS related to different circRNAs expressions was 2.63 (1.95-3.53) in BC with low heterogeneity (P=22.9%, P=0.268) and statistically significant (P < 0 .00001) (Figure 3). As is showed in figure 4, 28 included studies were divided into six subgroups by the cut-off value.We found that 2.0FC subgroup(P=87.1%) was the main source of heterogeneity.Furthermore, funnel plots of included studies relevant to circRNAs, OS, and DFS in BC patients were presented in Figures 5, and 6, respectively. These figures are approximately symmetrical, and we can think that there is no obvious publication bias.

4. Discussion

Breast cancer remians a huge threat to human health ,although new anticancer drugs are ongoing emergence on account of chemotherapy resistance and metastasis inducing poor prognosis. In the last decade, more and more studies focused on the clinical roles of circRNAs and many reports indicated that circRNAs can be a molecular biomarker in BC patients for predicting prognosis. However, few relevant meta analysis on the prognostic value of circRNAs expression existed in BC.

The purpose of this study was to elucidate the relationship between circRNAs expression and prognosis in breast cancer patients. Through big data meta-analysis, we provided evidence to demonstrate the prognostic value of abnormally expressed circRNAs in BC patients. The results of this meta-analysis showed that the pooled HR values (95%CI) of OS and DFS associated with different circRNAs expression in BC patients were 1.68 (1.44-1.97) and 2.63 (1.95-3.53), respectively, which suggested that the abnormally expressed circRNAs could be used as a cancer biomarker in BC patients. By detecting specific circRNAs expression levels in tissues or other body fluids, we can not only make appropriate clinical decisions based on different prognoses, but also monitor the treatment outcomes of BC patients receiving different treatments. The main role of circRNAs at the molecular level is to act as microRNA (miRNA) sponges and isolate miRNAs, thereby terminating the regulation of miRNA target genes [39, 40].

There is increasing evidence [41-46]that circRNAs play a key role in various cellular activities and are involved in various human diseases, including the proliferation, migration, invasion and cell cycle-related activities of cancer. The upregulation of circRNAs promoted the migration, invasion, EMT, proliferation and drug resistance of tumor cells, and inhibited the apoptosis of different target genes, which was related to poor prognosis. For example, Zang et al.[32]reported that circ_0000520 gene knockdown could inhibit the growth, migration and invasion of cells in vitro and in vivo by directly regulating Mir-1296 /SP1 pathway. The results showed that circ_0000520 was up-regulated in breast tumors and cell lines, and its high expression was associated with low overall survival rate. The down-regulated circRNAs with

overexpression can inhibit the migration, invasion and proliferation of tumor cells. Yan Ling et al.[25]found that circ_0072309 with overexpression could inhibit the proliferation, metastasis and invasion of breast cancer cells by inhibiting the Mir-492 pathway, and the results showed that overall survival rate of circ_0072309 with low expression was high campared to circ_0072309 with overexpression.

Therefore, circRNAs can be used as a molecular biomarker to predict the prognosis of BC patients. Several studies have shown that circRNA can be used as CeRNAS to regulate the proliferation and progression of BC through micro RNA sponges. There is increasing evidence that micrornas regulate gene expression during tumorigenesis. further studies have been found that some circRNAs, as microRNA sponges, are involved in the regulation of tumor proliferation, metastasis and invasion. For example,Bian et al. [34] found that Circular PVT1 was significantly overexpressed in breast cancer tissues and cell lines, and it plays a role of competitive endogenous RNA (CE RNA) by targeting Mir-204-5P. Circular PVT1 knockdown can inhibit the proliferation, invasion and metastasis of breast cancer cells. This study explored how the ceRNA mechanism of circRNA functioned in the oncogenesis and progression of breast cancer, providing a new perspective for basic research.In general, predicting patient outcomes and exploring the mechanisms of circRNA play a key role in clinical decision-making and the development of new targeted gene therapies.

we summarized the research on the mechanism of circRNA. We found that 28 studies showed specific targets for circRNAs, 9 circRNAs were down-regulated, and their overexpression could inhibit the proliferation, infiltration or metastasis of breast cancer cells. Nineteen circrnas were up-regulated, and their overexpression could promote proliferation, invasion or metastasis of breast cancer cells. These studies have shown that the potential relationship between circRNAs and microRNA plays a key role in the pathogenesis of tumors and promotes the research and development of oncogene therapy. Many studies focusing on the same circRNAs have revealed different targets, and the potential correlation between circRNAs and microRNA remains unclear. In the future, we should pay attention to the interaction between circRNAs and microRNA or other types of RNA, and achieve targeted therapy by intervening multiple types of RNA simultaneously.

However, there are some limitations in this study. First, most of the patients are from East Asia, especially China, which makes our conclusion only suitable for Chinese patients. Second, after the exclusion of the 2.0FC subgroup, meta analysis revealed a significant decrease in heterogeneity, which suggested that different cut-off values and detection methods for circRNAs expression in different studies may lead to heterogeneity among studies. Third, language bias is also a limitation, as we only register English papers in meta-analysis. Fourth, most authors are generally more likely to report positive results, so the calculated aggregate effect value may overestimate the predictive significance of circRNA in the prognosis of breast cancer patients. Consensus has been reached on publication bias. Fifth, we calculated HR estimates from the Kaplan-Meier survival curve, because some studies could not directly extract HR and 95%CI. Sixth, some confounding factors in studies may lead to high heterogeneity if there is no adjusted HR value.

In conclusion, this meta-analysis supports the fact that specific circRNAs is significantly associated with the prognosis of breast cancer patients and may serve as a new marker for predicting the prognosis of breast cancer patients. In addition, circRNAs may contribute

significantly to future circRNAs targeted therapy and clinical decision-making for breast cancer.

Figure 1: Study flow diagram.

 Table 1: Characteristics of studies and different circRNAs expression related to OS in BC patients.

 Table 2: Characteristics of studies and different circRNAs expression related to DFS in BC patients.

Table 3: circRNAs and target miRs in breast cancer.

Figure 2: Forest plot of OS associated with expression level of different circRNAs in BC patients was presented.

Figure 3: Forest plot of DFS associated with expression level of different circRNAs in BC patients was presented.

Figure 4: Forest plot of OS associated with expression level of different circRNAs in BC patients by subgroups

Figure 5: Funnel plots of studies associated with OS in this meta-analysis.

Figure 6: Funnel plots of studies associated with DFS in this meta-analysis.

References

[1]. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.

[2]. Ferlay, J., et al., Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 2019. 144(8): p. 1941-1953.

[3]. Salzman, J., Circular RNA Expression: Its Potential Regulation and Function. Trends Genet, 2016. 32(5): p. 309-316.

[4]. Chen, L.L. and L. Yang, Regulation of circRNA biogenesis. RNA Biol, 2015. 12(4): p. 381-8.

[5]. Qu, S., et al., Circular RNA: A new star of noncoding RNAs. Cancer Lett, 2015. 365(2): p. 141-8.

[6]. Memczak, S., et al., Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 2013. 495(7441): p. 333-8.

[7]. Su, M., et al., Circular RNAs in Cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers. Mol Cancer, 2019. 18(1): p. 90.

[8]. Wang, X. and L. Fang, Advances in circular RNAs and their roles in breast Cancer. J Exp Clin Cancer Res, 2018. 37(1): p. 206.

[9]. Li, X., L. Yang and L.L. Chen, The Biogenesis, Functions, and Challenges of Circular RNAs. Mol Cell, 2018. 71(3): p. 428-442.

[10]. Yang, L., et al., Circular RNA circ_0103552 forecasts dismal prognosis and promotes breast cancer cell proliferation and invasion by sponging miR-1236. J Cell Biochem, 2019. 120(9): p. 15553-15560.

[11]. Mao, Y., et al., Circular RNA 000554 represses epithelial-mesenchymal transition in breast cancer by regulating microRNA-182/ZFP36 axis. FASEB J, 2020.

[12]. Tierney, J.F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8: p. 16.

[13]. Li, Y. and H. Li, Circular RNA VRK1 correlates with favourable prognosis, inhibits cell

proliferation but promotes apoptosis in breast cancer. J Clin Lab Anal, 2020. 34(1): p. e22980.

[14]. Cao, L., et al., Circular RNA circRNF20 promotes breast cancer tumorigenesis and Warburg effect

through miR-487a/HIF-1a/HK2. Cell Death Dis, 2020. 11(2): p. 145.

[15]. Liu, M., et al., CircRNA_103809 Suppresses the Proliferation and Metastasis of Breast Cancer Cells by Sponging MicroRNA-532-3p (miR-532-3p). Front Genet, 2020. 11: p. 485.

[16]. Xu, G., et al., circNFIC suppresses breast cancer progression by sponging miR-658. J Cancer, 2020. 11(14): p. 4222-4229.

[17]. Song, X., et al., circHMCU Promotes Proliferation and Metastasis of Breast Cancer by Sponging the let-7 Family. Mol Ther Nucleic Acids, 2020. 20: p. 518-533.

[18]. Zhou, H., et al., circFBXL5 promotes breast cancer progression by sponging miR-660. J Cell Mol Med, 2020. 24(1): p. 356-361.

[19]. Liang, G., et al., Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. Mol Cancer, 2020. 19(1): p. 65.

[20]. Liang, Y., et al., Targeting the circBMPR2/miR-553/USP4 Axis as a Potent Therapeutic Approach for Breast Cancer. Mol Ther Nucleic Acids, 2019. 17: p. 347-361.

[21]. Xie, R., et al., Silencing of hsa_circ_0004771 inhibits proliferation and induces apoptosis in breast cancer through activation of miR-653 by targeting ZEB2 signaling pathway. Biosci Rep, 2019. 39(5).

[22]. Xu, Y., et al., Increased Expression of Circular RNA circ_0005230 Indicates Dismal Prognosis in Breast Cancer and Regulates Cell Proliferation and Invasion via miR-618/ CBX8 Signal Pathway. Cell Physiol Biochem, 2018. 51(4): p. 1710-1722.

[23]. Wang, S., et al., CircZNF609 promotes breast cancer cell growth, migration, and invasion by elevating p70S6K1 via sponging miR-145-5p. Cancer Manag Res, 2018. 10: p. 3881-3890.

[24]. Xu, J.H., Y. Wang and D. Xu, Hsa_circ_001569 is an unfavorable prognostic factor and promotes cell proliferation and metastasis by modulating PI3K-AKT pathway in breast cancer. Cancer Biomark, 2019. 25(2): p. 193-201.

[25]. Yan, L., M. Zheng and H. Wang, Circular RNA hsa_circ_0072309 inhibits proliferation and invasion of breast cancer cells via targeting miR-492. Cancer Manag Res, 2019. 11: p. 1033-1041.

[26]. Liang, Y., et al., circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene, 2019. 38(42): p. 6850-6866.

[27]. Wang, N., et al., Circular RNA circMYO9B facilitates breast cancer cell proliferation and invasiveness via upregulating FOXP4 expression by sponging miR-4316. Arch Biochem Biophys, 2018. 653: p. 63-70.

[28].Zeng, K., et al., The pro-metastasis effect of circANKS1B in breast cancer. Mol Cancer, 2018. 17(1): p. 160.

[29]. Wang, Y., et al., Upregulated Circular RNA circ-UBE2D2 Predicts Poor Prognosis and Promotes Breast Cancer Progression by Sponging miR-1236 and miR-1287. Transl Oncol, 2019. 12(10): p. 1305-1313.

[30]. Gao, D., et al., hsa_circRNA_0006528 as a competing endogenous RNA promotes human breast cancer progression by sponging miR-7-5p and activating the MAPK/ERK signaling pathway. Mol Carcinog, 2019. 58(4): p. 554-564.

[31]. Zhang, X., et al., Circular RNA La-related RNA-binding protein 4 correlates with reduced tumor stage, as well as better prognosis, and promotes chemosensitivity to doxorubicin in breast cancer. J Clin Lab Anal, 2020. 34(7): p. e23272.

[32]. Zang, H., et al., Blocking circ_0000520 Suppressed Breast Cancer Cell Growth, Migration and Invasion Partially via miR-1296/SP1 Axis Both in vitro and in vivo. Cancer Manag Res, 2020. 12: p. 7783-7795.

[33]. Lin, X., et al., TV-circRGPD6 Nanoparticle Suppresses Breast Cancer Stem Cell-Mediated Metastasis via the miR-26b/YAF2 Axis. Mol Ther, 2020.

[34]. Chen, Z.G., et al., Circular RNA CirCHIPK3 promotes cell proliferation and invasion of breast cancer by sponging miR-193a/HMGB1/PI3K/AKT axis. Thorac Cancer, 2020. 11(9): p. 2660-71.

[35]. Bian, Q., Circular RNA PVT1 promotes the invasion and epithelial-mesenchymal transition of breast cancer cells through serving as a competing endogenous RNA for miR-204-5p. Onco Targets Ther, 2019. 12: p. 11817-11826.

[36]. Cai, F., et al., Hsa_circ_0000515 is a novel circular RNA implicated in the development of breast cancer through its regulation of the microRNA-296-5p/CXCL10 axis. FEBS J, 2020.

[37]. Li, W., et al., Hsa_circ_002178 Promotes the Growth and Migration of Breast Cancer Cells and Maintains Cancer Stem-like Cell Properties Through Regulating miR-1258/KDM7A Axis. Cell Transplant, 2020. 29: p. 963689720960174.

[38]. Liu, Z., et al., Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis, 2019. 10(2): p. 55.

[39]. Hansen, T.B., et al., Natural RNA circles function as efficient microRNA sponges. Nature, 2013. 495(7441): p. 384-8.

[40]. Sumazin, P., et al., An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell, 2011. 147(2): p. 370-81.

[41].Panda, A.C., et al., Emerging roles and context of circular RNAs. Wiley Interdiscip Rev RNA, 2017. 8(2).

[42]. Panda, A.C., et al., Identification of senescence-associated circular RNAs (SAC-RNAs) reveals senescence suppressor CircPVT1. Nucleic Acids Res, 2017. 45(7): p. 4021-4035.

[43]. Xie, H., et al., Emerging roles of circRNA_001569 targeting miR-145 in the proliferation and invasion of colorectal cancer. Oncotarget, 2016. 7(18): p. 26680-91.

[44]. Du WW, et al., Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res, 2016. 44(6): p. 2846-58.

[45]. Wang, Y., et al., Circular RNAs in human cancer. Mol Cancer, 2017. 16(1): p. 25.

[46]. Li, P., et al., Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta, 2015. 444: p. 132-6.



ID	HR (95% CI)	Weight
Yang etal/circ 0103552+ (2019) medRxiv preprint doi: https://doi.org/10.1101/2021.01.02/21249132; this version posted January 4, 2021. The copyright holder for this preprint	2.32 (1.03, 5.23)	4.54
Yang etal/circ 0103552+ (2019) medRxiv preprint doi: https://doi.org/10.1101/2021.01.02/21249132; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Yan etal/hsa_circ_0012 medeava[200 frger a CC-BY-ND 4.0 International license .	1.73 (0.36, 8.42)	1.88
Xu etal/circ_0005230↑ (2018)	1.95 (1.02, 3.70)	5.60
Xu etal/Hsa_circ_001569† (2019)	3.03 (1.33, 4.24)	6.06
Wang etal/circUBE2D2↑ (2019)	1.39 (0.12, 16.01)	0.89
Wang etal/MYO9B↑ (2018)	2.79 (0.27, 29.23)	0.96
Liang etal/circKDM4C↓ (2019)	0.17 (0.03, 0.98)	1.57
Gao etal/hsa_circRNA_0006528↑ (2018)	1.39 (0.44, 4.36)	3.02
Xie etal/hsa_circ_0004771↑ (2019)	1.49 (0.83, 2.68)	6.01
Zeng etal/ANKS1B↑ (2019)	3.29 (1.36, 7.93)	4.16
Cao etal/circRNF20↑ (2020)	1.26 (0.44, 3.57)	3.40
Liang etal/BMPR2↓ (2019)	0.45 (0.28, 0.75)	6.65
Liang etal/circCDYL↑ (2020)	3.75 (1.23, 11.24)	3.16
Zhou etal/FBXL5† (2019)	1.73 (0.41, 7.33)	2.17
Song etal/CircHMCU↑ (2020)	3.09 (1.44, 6.66)	4.81
Xu etal/CIRCNFIC↓ (2020)	2.81 (0.26, 29.83)	0.94
Liu etal/CircRNA_103809↓ (2020)	1.06 (0.30, 3.85)	2.60
Li etal/Circ-VRK1↓ (2019)	2.08 (1.07, 4.03)	5.47
wang etalCircZNF609↑ (2018)	1.16 (0.44, 3.03)	3.76
Zhang etal/circ-LARP4↓ (2019)	1.94 (1.85, 4.45)	7.11
Mao etal/circ000554 (2020)	1.63 (0.80, 3.32)	5.15
Zang etal/circ_0000520↑ (2020)	1.50 (0.18, 12.50)	1.15
Chen etal/CirCHIPK3↑ (2020)	1.69 (0.14, 20.22)	0.86
Lin etal/TV-circRGPD6↓ (2020)	2.45 (1.50, 4.01)	6.71
Bian etal/Circular PVT1↑ (2020)	1.60 (0.64, 4.00)	3.99
Cai etal/circ0000515† (2020)	1.39 (0.69, 2.82)	5.20
Li etal/Hsa_circ_002178↑ (2020)	1.34 (0.32, 5.62)	2.19
Overall (I-squared = 47.9%, p = 0.003)	1.69 (1.33, 2.16)	100.00
NOTE: Weights are from random effects analysis	÷	
.0288 1	34.7	

%

Study

Study

medRxiv preprint doi: https://doi.org/10.1101/2021.01.02.21249132; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

ID

Liang etal/circCDYL† (2020)

Liu etal/circ_001783† (2019)

Wang etal/circUBE2D2† (2019)

Zhang etal/ciro-LARP41 (2019)

Lin etal/circRGPD61 (2020)

Overall (I-squared = 22.9%, p = 0.268)

2.85 (1.42, 5.73) 18.03 9.11 (2.42, 34.20) 5.00 1 1.50 (0.37, 6.16) 4.44 31.33 2.00 (1.18, 3.40) 2.85 (1.80, 4.53) 41.20 2.63 (1.95, 3.53) 100.00

% Weight

HR (95% CI)

Study ID	HR (95% CI)	% Weight
Mean		- 11-12 (2014)
Yang etal/circ_0103552↑ (2019)	2.32 (1.03, 5.23)	4.54
Mao etal/circ0005541 (2020)	1.63 (0.80, 3.32)	5.15
medRaw preprint (0) (1055/15 or (20) 20) 201/2021.01.02.21249132; this version posted January 4, 2021. The copyright belder or the proprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.	1.39 (0.69, 2.82)	5.20
Subtotal (I-squared = 0.0% mpde available under a CC-BY-ND 4.0 International license .	1.69 (1.11, 2.59)	14.89
NR		
Yan etal/hsa_circ_00723091 (2019)	1.73 (0.36, 8.42)	1.88
Wang etal/MYO9B† (2018)	2.79 (0.27, 29.23)	0.96
Cao etal/circRNF20 ⁺ (2020)	1.26 (0.44, 3.57)	3.40
Subtotal (I-squared = 0.0%, p = 0.816)	1.51 (0.67, 3.42)	6.24
Median		
Xu etal/circ_0005230† (2018)	1.95 (1.02, 3.70)	5.60
Xu etal/Hsa_circ_001569† (2019)	3.03 (1.33, 4.24)	6.06
Wang etal/circUBE2D2 [↑] (2019)	1.39 (0.12, 16.01)	0.89
Gao etal/hsa_circRNA_0006528↑ (2018)	1.39 (0.44, 4.36)	3.02
Zeng etal/ANKS1B† (2019)	3.29 (1.36, 7.93)	4.16
Liang etal/circCDYL↑ (2020)	3.75 (1.23, 11.24)	3.16
Song etal/CircHMCU [↑] (2020)	3.09 (1.44, 6.66)	4.81
Liu etal/CircRNA_1038091 (2020)	1.06 (0.30, 3.85)	2.60
Li etal/Circ-VRK11 (2019)	2.08 (1.07, 4.03)	5.47
wang etalCircZNF609† (2018)	1.16 (0.44, 3.03)	3.76
Zhang etal/circ-LARP41 (2019)	1.94 (1.85, 4.45)	7.11
Zang etal/circ_0000520† (2020)	1.50 (0.18, 12.50)	1.15
Chen etal/CirCHIPK3† (2020)	1.69 (0.14, 20.22)	0.86
Bian etal/Circular PVT1↑ (2020)	1.60 (0.64, 4.00)	3.99
Li etal/Hsa_circ_002178† (2020)	1.34 (0.32, 5.62)	2.19
Subtotal (I-squared = 0.0%, p = 0.847)	2.11 (1.70, 2.62)	54.82
1.5FC		
Liang etal/circKDM4C1 (2019)	0.17 (0.03, 0.98)	1.57
Subtotal (I-squared = .%, p = .)	0.17 (0.03, 0.98)	1.57
1.0FC		
Xie etal/hsa_circ_0004771↑ (2019)	1.49 (0.83, 2.68)	6.01
Subtotal (I-squared = .%, p = .)	1.49 (0.83, 2.68)	6.01
2.0FC		
Liang etal/BMPR21 (2019)	0.45 (0.28, 0.75)	6.65
Zhou etal/FBXL5† (2019)	1.73 (0.41, 7.33)	2.17
Xu etal/CIRCNFIC1 (2020)	2.81 (0.26, 29.83)	0.94
Lin etal/TV-circRGPD61 (2020)	2.45 (1.50, 4.01)	6.71
Subtotal (I-squared = 87.1%, p = 0.000)	1.35 (0.42, 4.35)	16.47
	1.00 (0.42, 4.00)	10.41
Overall (I-squared = 47.9%, p = 0.003)	1.69 (1.33, 2.16)	100.00
NOTE: Weights are from random effects analysis		2
	17	
.0288 1 34	4.7	

Funnel plot with pseudo 95% confidence limits





-4	CircRNA		Nistis a	Number		os	cut-off	Sample	Detecti
study	(n=27)	year	Nation	(n=3636)	HR	95%Cl	value	types	metho
Yang etal	circ_0103552↑	2019	China	57	2.32	1.03-5.23	Mean	Tissue	RT-PC
Yan etal	hsa_circ_0072309↓	2019	China	32	1.73	0 36-8 42	NR	Tissue	RT-PC
Xu etal	circ_0005230 †	2018	China	76	1.95	1.02-3.70	Median	Tissue	RT-PC
Xu etal	Hsa_circ_001569 t	2019	China	145	3.03	1.33-4.24	Median	Tissue	RT-PC
Wang etal	circUBE2D21	2019	China	80	1.39	0.12-16.01	Median	Tissue	RT-PC
Wang etal	MYO9B†	2018	China	41	2.79	0.27-29.23	NR	Tissue	RT-PC
Liang etal	circKDM4C↓	2019	China	219	0.1687	0.0288-0.98	1.5FC	Tissue	RT-PC
Gao etal	hsa_circRNA_0006528 t	2018	China	96	1.39	0.44-4.36	Median	Tissue	RT-PC
Xie etal	hsa_circ_0004771†	2019	China	51	1.49	0.83-2.68	1.0FC	Tissue	RT-PC
Zeng etal	ANKS1B†	2019	China	165	3.29	1 36-7 93	Median	Tissue	RT-PC
Cao etal	circRNF201	2020	China	50	1.26	0.44-3.57	NR	Tissue	RT-PC
Liang etal	BMPR2↓	2019	China	199	0.4539	0.275-0.746	2.0FC	Tissue	RT-PC
Liang etal	circCDYL †	2020	China	30	3.75	1.23-11.24	Median	Tissue	RT-PC
Zhou etal	FBXL5†	2019	China	150	1.73	0.41-7.33	2.0FC	Tissue	RT-PC
Song etal	CircHMCU†	2020	China	267	3.09	1.44-6.66	Median	Tissue	RT-PC
Xu etal	CIRCNFIC↓	2020	China	150	2.81	0.26-29.83	2.0FC	Tissue	RT-PC
Liu etal	CircRNA_103809↓	2020	China	65	1.06	0.3-3.85	Median	Tissue	RT-PC
Li etal	Circ-VRK1 †	2019	China	350	2.08	1.07-4.03	Median	Tissue	RT-PC
wang etal	CircZNF6091	2018	China	143	1.16	0.44-3.03	Median	Tissue	RT-PC
Zhang etal	circ-LARP4↓	2019	China	283	1.94	1.85-4.45	Median	Tissue	RT-PC
Mao etal	circ000554↓	2020	China	138	1.63	0.8-3.32	Mean	Tissue	RT-PC
Zang etal	circ_00005201	2020	China	60	1.5	0.18-12.5	Median	Tissue	RT-PC
Chen etal	CirCHIPK3 †	2020	China	50	1.69	0.14-20.22	Median	Tissue	RT-PC
Lin etal	TV-circRGPD6↓	2020	China	217	2.45	1.5-4.01	2.0FC	Tissue	RT-PC
Bian etal	Circular PVT1 †	2020	China	99	1.6	0.64-4	Median	Tissue	RT-PC
Cai etal	circ0000515 †	2020	China	340	1.39	0.69-2.82	Mean	Tissue	RT-PC
Li etal	Hsa_circ_0021781	2020	China	83	1.34	0.32-5.62	Median	Tissue	RT-PC

Table1: Characteristics of studies and different circRNAs expression related to OS in BC patients

BC breast cancer; t or Lup-regulated or down-regulated with poor prognosis; OS overall survival; HR hazard ratio; NR

not report; FC fold change ;RT-PCR reverse transcription PCR.

study	circRNA	year	Natio	Number		DFS	cut-off	Sampl	Detection	Follow-up
	(n=5)		n	(n=829)	HR	95 %Cl	value	e types	methods	(month)
Liang etal	circCDYL1	2020	China	113	2.85	1 42-5 7	Median	Tissue	RT-PCR	120
						3				
Liu etal	circ_001783	2019	China	136	9.11	2.42-34	Mean	Tissue	RT-PCR	80
	t					2				
Wang etal	circUBE2D	2019	China	80	1.5	0.37-6.1	Median	Tissue	RT-PCR	100
	21					6				
Zhang et	circ-LARP4	2019	China	283	2	1.18-3.4	Median	Tissue	RT-PCR	60
al	Ļ									
Lin etal	circRGPD6	2020	China	217	2.85	1.8-4.53	2.0FC	Tissue	RT-PCR	100-120
	ţ									

Table 2: Characteristics of studies and	different circRNAs expression	related to DFS in BC patients

BC; breast cancert or↓ up-regulated or down-regulated with poor prognosis; DFS disease free survival; HR hazard ratio; RT-PCR reverse transcription PCR; FC fold change

Table3: circRNAs and target miRs in breast cancer

circRNA(n=28)	Poor prognosis	Role	Function
Circ-VRK1	Downregulated	Suppressor	Proliferation/apoptosis
circRNF20	Upregulated	Oncogene	Progression/glycolysis
CircRNA_103809	Downregulated	Suppressor	Proliferation/Metastasis
CIRCNFIC	Downregulated	Suppressor	Proliferation/migration
CircHMCU	Upregulated	Oncogene	Proliferation/metastasis/EMT
FBXL5	Upregulated	Oncogene	Proliferation/migration
circCDYL	Upregulated	Oncogene	Proliferation
BMPR2	Downregulated	Suppressor	Metastasis
circ_001783	Upregulated	Oncogene	Proliferation/metastasis
hsa_circ_0004771	Upregulated	Oncogene	Proliferation
circ_0005230	Upregulated	Oncogene	Proliferation/migration/Invasion
circ_0103552	Upregulated	Oncogene	Proliferation/migration/invasion
CircZNF609	Upregulated	Oncogene	Proliferation/migration/invasion
Hsa_circ_001569	Upregulated	Oncogene	Proliferation/metastasis/EMT
hsa_circ_0072309	Downregulated	Suppressor	Proliferation/migration/invasion
ANKS1B	Upregulated	Oncogene	Migration/invasion/metastasis/EM1
KDM4C	Downregulated	Suppressor	Proliferation/migration/invasion

MYO9B	Upregulated	Oncogene	Proliferation/migration/invasion
circUBE2D2	Upregulated	Oncogene	Proliferation/migration/invasion
hsa_circRNA_0006528	Upregulated	Oncogene	Proliferation/migration/invasion
circ-LARP4	Downregulated	Suppressor	Proliferation/migration/invasion
circ000554	Downregulated	Suppressor	Migration/invasion/metastasis/EMT
circ_0000520	Upregulated	Oncogene	Proliferation/migration/invasion
TV-circRGPD6	Downregulated	Suppressor	Metastasis
CirCHIPK3	Upregulated	Oncogene	Proliferation/migration/invasion
Circular PVT1	Upregulated	Oncogene	Proliferation/migration/invasion
circ0000515	Upregulated	Oncogene	Proliferation/invasion
Hsa_circ_002178	Upregulated	Oncogene	Proliferation/migration/invasion